Flinton Capital Management LLC held its position in shares of ICON PLC (NASDAQ:ICLR) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,664 shares of the medical research company’s stock at the end of the 2nd quarter. Flinton Capital Management LLC’s holdings in ICON PLC were worth $163,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Principal Financial Group Inc. raised its position in ICON PLC by 16.8% in the 2nd quarter. Principal Financial Group Inc. now owns 448,115 shares of the medical research company’s stock valued at $43,821,000 after purchasing an additional 64,456 shares during the last quarter. Wesbanco Bank Inc. raised its position in ICON PLC by 18.6% in the 2nd quarter. Wesbanco Bank Inc. now owns 18,044 shares of the medical research company’s stock valued at $1,765,000 after purchasing an additional 2,830 shares during the last quarter. Bank of New York Mellon Corp raised its position in ICON PLC by 0.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 312,735 shares of the medical research company’s stock valued at $30,582,000 after purchasing an additional 1,947 shares during the last quarter. Morgan Stanley raised its position in ICON PLC by 89.8% in the 1st quarter. Morgan Stanley now owns 147,238 shares of the medical research company’s stock valued at $11,737,000 after purchasing an additional 69,669 shares during the last quarter. Finally, Fox Run Management L.L.C. purchased a new stake in ICON PLC in the 2nd quarter valued at $626,000. Hedge funds and other institutional investors own 91.54% of the company’s stock.

Shares of ICON PLC (NASDAQ:ICLR) opened at 113.63 on Monday. ICON PLC has a 52 week low of $73.76 and a 52 week high of $117.53. The firm has a market capitalization of $6.14 billion, a PE ratio of 23.05 and a beta of 0.59. The company has a 50-day moving average of $113.18 and a 200-day moving average of $98.33.

ICON PLC (NASDAQ:ICLR) last released its earnings results on Thursday, July 27th. The medical research company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.01. The firm had revenue of $431.00 million for the quarter, compared to analyst estimates of $430.68 million. ICON PLC had a return on equity of 28.72% and a net margin of 15.97%. ICON PLC’s revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.14 earnings per share. On average, equities analysts forecast that ICON PLC will post $5.32 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was first published by Watch List News and is the property of of Watch List News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/flinton-capital-management-llc-has-163000-stake-in-icon-plc-iclr/1634488.html.

Several equities analysts have issued reports on the stock. Zacks Investment Research cut shares of ICON PLC from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. ValuEngine raised shares of ICON PLC from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. Jefferies Group LLC raised shares of ICON PLC from a “hold” rating to a “buy” rating and boosted their price objective for the company from $86.00 to $117.00 in a research note on Thursday, June 29th. Robert W. Baird reissued a “buy” rating and issued a $123.00 price objective on shares of ICON PLC in a research note on Thursday. Finally, BidaskClub raised shares of ICON PLC from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. Four equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $117.33.

About ICON PLC

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Institutional Ownership by Quarter for ICON PLC (NASDAQ:ICLR)

Receive News & Ratings for ICON PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.